NRG1 Fusions in Lung and GI Cancers

December 4, 2023

By Alexander Spira, MD, PhD, FACP
Joshua K. Sabari, MD

Opinion

Video

Alexander I. Spira, MD, PhD, and Joshua K. Sabari, MD, discuss the prevalence of NRG1 fusions in pulmonary and gastrointestinal solid tumors and provide an overview of treatment practices.

EP: 1.Overview of NRG1 Fusions

EP: 2.NRG1 Fusion Testing Practices

EP: 3.Recent Data on Zenocutuzumab at ESMO 2023

EP: 4.Practical Considerations for Zenocutuzumab in NRG1 Fusion–Positive Malignancies

EP: 5.Clinical Pearls on Treating Patients with NRG1 Fusions

Now Viewing

EP: 6.NRG1 Fusions in Lung and GI Cancers

EP: 7.Testing for NRG1 Fusions

EP: 8.Clinical Diagnosis of NRG1 Fusions in NSCLC

EP: 9.Ongoing Research of NRG1-Targeted Therapies

EP: 10.NRG1 Fusions in Pancreatic Cancer and Potential Role of Zenocutuzumab

EP: 11.Key Takeaways for the Treatment of NRG1 Fusion–Positive Malignancies

EP: 12.Defining a Space for NRG1 Fusion–Positive Tumors in Lung and GI Cancers

EP: 13.Inpatient vs Outpatient Use of Teclistamab in Multiple Myeloma

Educational support for this activity provided by Merus.

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!